Published in Cancer Weekly, November 11th, 2003
The study, entitled "A Multicenter Phase I Safety Study of Intratumoral Photoactivation of Talaporfin Sodium (LS11) in Patients with Refractory Solid Tumors," is authored by a 10-member international research team led by Robert Lustig, MD, department of radiation oncology, Hospital of the University of Pennsylvania, Philadelphia.
The study appeared in the October 15, 2003, issue of the journal "Cancer."
Litx is designed to treat localized disease and is initially being studied...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.